Sartorius (SARTF) Stock Rating Upgraded by Zacks Investment Research

Sartorius (OTCMKTS:SARTF) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Wednesday. The brokerage presently has a $150.00 price objective on the stock. Zacks Investment Research‘s price target suggests a potential upside of 11.77% from the company’s previous close.

According to Zacks, “Sartorius AG is a pharmaceutical and laboratory equipment supplier. The company manufactures equipment for biomolecular and microbial separations, cell culture, concentration, fermentation and purification. Sartorius AG is headquartered in Goettingen, Germany. “

Shares of SARTF opened at $134.21 on Wednesday. Sartorius has a 12-month low of $124.00 and a 12-month high of $149.00. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.00 and a current ratio of 1.62. The stock has a market cap of $5.02 billion, a P/E ratio of 71.77 and a beta of 0.08.

Sartorius (OTCMKTS:SARTF) last issued its quarterly earnings results on Tuesday, October 23rd. The company reported $0.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.05. Sartorius had a return on equity of 20.21% and a net margin of 9.09%. The firm had revenue of $459.56 million for the quarter, compared to analyst estimates of $460.00 million. Analysts anticipate that Sartorius will post 2.98 EPS for the current fiscal year.

Sartorius Company Profile

There is no company description available for Sartorius AG.

Featured Story: Book Value Of Equity Per Share – BVPS Explained

Get a free copy of the Zacks research report on Sartorius (SARTF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Sartorius Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply